Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics

Table 6 Traditional pharmacologic preventives for pediatric migraine: Rapid comparison

Agent	Topiramate	Amitriptyline	Propranolol
Mechanism of action	Enhances GABAergic inhibition; inhibits glutamatergic transmission; ion channel modulation	Serotonergic and noradrenergic reuptake inhibition	Non-selective β-adrenergic blockade
Strength of evidence (pediatrics)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Moderate (FDA-approved ≥ 12 years; CHAMP showed no superiority to placebo)	Low-moderate (small trials, mixed results)
Typical starting pediatric dose1	Start 0.5-1 mg/kg/day	Start 0.25-0.5 mg/kg at bedtime	0.5 mg/kg (divided)
Titration (weekly)	Increase by 0.5 mg/kg to 1-2 mg/kg/day	Increase by 0.25 mg/kg	Increase by 0.5 mg/kg
Max dose	Max 100 mg/day	Max 1 mg/kg/day (usually ≤ 50 mg)	2-4 mg/kg (max 160 mg)
Key limitations/monitoring	Cognitive slowing, paresthesia, weight loss	Sedation, weight gain, anticholinergic effects	Contraindicated in children with asthma or diabetes
Practical considerations	Avoid children with learning difficulties; monitor weight, cognition, and mood	Baseline ECG recommended; high placebo response	May benefit comorbid anxiety; monitor heart rate blood pressure and exercise tolerance
Contraindication	Nephrolithiasis, glaucoma	Cardiac conduction defects	Asthma, diabetes, depression

¹Doses reflect commonly used ranges from pediatric headache guidelines and expert consensus; individualization and slow titration are recommended.

GABA: Gamma-aminobutyric acid; FDA: Food and Drug Administration; ECG: Electrocardiogram.